|Last||Chg. %||Chg. Abs.||ISIN||Date, Time||MPQ|
Information Dissemination System
Mr. Franck Grimaud, President & CBO
Mr. David Lawrence, CFO
Mr. Wolfgang Bender, CMO
Mr. Frederic Jacotot, General Counsel
Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC.
The Company has proprietary vaccines in development including a unique vaccine against Lyme disease.
Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with over 450 employees.
More information is available at www.valneva.com.
|02/15/2018||Preliminary results 2017|
|03/22/2018||Financial statements 2017|
|05/17/2018||Results on the 1st quarter 2018|
|06/25/2018||Record date "Annual General Meeting" (according to French Corporate law)|
|06/28/2018||Annual General Meeting|
|07/09/2018||Record date "dividends"|
|07/10/2018||Dividend payment date|
|08/02/2018||Results on the 1st half-year 2018|
|11/08/2018||Results on the 3rd quarter 2018|
Source: provided by the company
Record date "Dividends": Date on which settled positions are struck in the books of the Issuer`s CSD at close of business to determine the entitlement to dividends. Origination of entitlement is still linked to the Ex-dividend date.
Record date "Annual General Meeting": Date for participation to Annual General Meeting.